Epidermal Growth Factor Receptor Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Epidermal Growth Factor Receptor stocks.

Epidermal Growth Factor Receptor Stocks Recent News

Date Stock Title
May 10 AZTR Azitra GAAP EPS of -$0.15
May 10 AZTR Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
May 9 AZTR Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
May 9 OLMA Olema Pharmaceuticals GAAP EPS of -$0.56 beats by $0.02
May 9 BMY Q1 2024 Editas Medicine Inc Earnings Call
May 8 OLMA Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8 ZNTL Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
May 8 OLMA Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 8 BMY Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
May 8 ZNTL Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
May 7 BMY A Look at Pharma ETFs Post Q1 Earnings
May 7 ZNTL Zentalis Pharmaceuticals GAAP EPS of $0.14, revenue of $40.56M
May 7 ZNTL Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
May 6 BMY FDA accepts Bristol Myers application for injected Opdivo
May 6 BMY European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
May 6 BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 5 PBYI Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
May 5 AZTR Wall Street Breakfast: The Week Ahead
May 5 PBYI Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 4 BMY Pharma R&D productivity seen improving for the first time in years - Deloitte
Epidermal Growth Factor Receptor

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.Epidermal growth factor and its receptor was discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.
Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.

Browse All Tags